JP2024533356A5 - - Google Patents

Info

Publication number
JP2024533356A5
JP2024533356A5 JP2024515317A JP2024515317A JP2024533356A5 JP 2024533356 A5 JP2024533356 A5 JP 2024533356A5 JP 2024515317 A JP2024515317 A JP 2024515317A JP 2024515317 A JP2024515317 A JP 2024515317A JP 2024533356 A5 JP2024533356 A5 JP 2024533356A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
optionally substituted
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/119214 external-priority patent/WO2023041006A1/zh
Publication of JP2024533356A publication Critical patent/JP2024533356A/ja
Publication of JP2024533356A5 publication Critical patent/JP2024533356A5/ja
Pending legal-status Critical Current

Links

JP2024515317A 2021-09-16 2022-09-16 抗ｈｅｒ３抗体薬物複合体及びその組成物並びに用途 Pending JP2024533356A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111085308 2021-09-16
CN202111085308.7 2021-09-16
PCT/CN2022/119214 WO2023041006A1 (zh) 2021-09-16 2022-09-16 抗her3抗体药物偶联物及其组合物和用途

Publications (2)

Publication Number Publication Date
JP2024533356A JP2024533356A (ja) 2024-09-12
JP2024533356A5 true JP2024533356A5 (https=) 2025-10-02

Family

ID=85602455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515317A Pending JP2024533356A (ja) 2021-09-16 2022-09-16 抗ｈｅｒ３抗体薬物複合体及びその組成物並びに用途

Country Status (11)

Country Link
US (1) US20250018052A1 (https=)
EP (1) EP4389153A4 (https=)
JP (1) JP2024533356A (https=)
KR (1) KR20240056587A (https=)
CN (3) CN115957339A (https=)
AU (1) AU2022345316A1 (https=)
CA (1) CA3231491A1 (https=)
IL (1) IL311324A (https=)
MX (1) MX2024003025A (https=)
TW (2) TW202327661A (https=)
WO (2) WO2023041006A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024263367A1 (en) * 2023-04-27 2025-11-13 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate
CN120957758A (zh) * 2023-05-12 2025-11-14 四川科伦博泰生物医药股份有限公司 大环化合物及其制备方法和用途
WO2024235131A1 (zh) * 2023-05-12 2024-11-21 四川科伦博泰生物医药股份有限公司 大环类药物偶联物及其制备方法和用途
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor
EP4725969A1 (en) * 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
CN116444672B (zh) * 2023-06-13 2023-11-03 上海偌妥生物科技有限公司 人表皮生长因子3的抗体、其制备方法及其应用
WO2025092965A1 (zh) * 2023-11-03 2025-05-08 正大天晴药业集团股份有限公司 抗体药物偶联物的制备方法
CN119925630A (zh) * 2023-11-03 2025-05-06 正大天晴药业集团南京顺欣制药有限公司 抗体药物偶联物的制备方法
CN117257977A (zh) * 2023-11-07 2023-12-22 正大天晴药业集团南京顺欣制药有限公司 用于制备抗体药物偶联物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
PE20231050A1 (es) * 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
CN109422811A (zh) 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
WO2020059772A1 (ja) * 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
CN111116745B (zh) * 2018-11-01 2022-10-14 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用
WO2021022678A1 (zh) * 2019-08-07 2021-02-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物及其应用
WO2021090062A1 (en) * 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
EP4088739A4 (en) * 2019-12-23 2024-11-13 Eisai R&D Management Co., Ltd. PROCESS FOR PRODUCING ANTIBODY-DRUG CONJUGATE BASED ON ERIBULIN
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
TWI888610B (zh) * 2020-07-27 2025-07-01 大陸商上海拓界生物醫藥科技有限公司 抗ｃｄ７９ｂ抗體藥物偶聯物、其製備方法及其醫藥用途
EP4183421A4 (en) 2020-08-13 2025-04-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody drug conjugate
WO2022104697A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity
WO2022105878A1 (en) * 2020-11-20 2022-05-27 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Modified egfr antibody with reduced affinity, drug conjugate, and use thereof

Similar Documents

Publication Publication Date Title
JP2024533356A5 (https=)
JP2023542066A5 (https=)
JP2023539715A5 (https=)
JP2020019787A5 (https=)
JP2010535713A5 (https=)
JP2017095457A5 (https=)
JP2015528818A5 (https=)
RU2014146951A (ru) Конъюгаты типа лиганд dr5-лекарственное средство
CN116813631A (zh) 一种喜树碱类化合物及其偶联物
RU2016111131A (ru) Способы конъюгации сайт-специфических антител и композиции
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
JP2018537975A5 (https=)
JP2012522513A5 (https=)
JP2023527962A5 (https=)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2015527318A5 (https=)
JP2020526584A5 (https=)
JP2015523380A5 (https=)
JP2012522512A5 (https=)
JP2023545096A5 (https=)
JP2017510661A5 (https=)
RU2011144141A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2014502955A5 (https=)
RU2018119683A (ru) Сайт-специфические конъюгаты антитела к her2 и лекарственного средства